Canada Opens Legal Pathway for Access to Psychedelic Treatment with MDMA, Psilocbyin, More... (1/11/22)

The nation’s top spook announces an easing of rules around past marijuana use and national security clearances, the New Jersey legislature approves needle exchange expansion and syringe decriminalization bills, and more.

[image:1 align:left caption:true]Marijuana Policy

Director of National Intelligence Gives Clarification on Marijuana Issues and Clearance Holders. In guidance released late last year, Director of National Intelligence Avril Haines clarified the intelligence community’s policy regarding security clearances for people who have used marijuana. Under previous policy, people needed to have not used marijuana for one to two years before applying for a national security position, but now the policy is that past marijuana use should not be determinative, but that they needed to stop using if they were being considered for a position: “In light of the long-standing federal law and policy prohibiting illegal drug use while occupying a sensitive position or holding a security clearance, agencies are encouraged to advise prospective national security workforce employees that they should refrain from any future marijuana use upon initiation of the national security vetting process, which commences once the individual signs the certification contained in the Standard Form 86 (SF-86), Questionnaire for National Security Positions.”

The new guidance also addresses investing in marijuana businesses, warning that people seeking clearances should not do so, and it warns people seeking security clearances to be wary of using CBD products—although it doesn’t forbid it. “With respect to the use of CBD products, agencies should be aware that using these cannabis derivatives may be relevant to adjudications in accordance with SEAD 4.” In other words, it could show up on a drug test.

Virginia Republican Files Bill to Eliminate Social Equity Funding in Marijuana Program. State Sen. Thomas Norment Jr. has filed a bill, Senate Bill 107, that would eliminate social equity funding for the state’s recreational marijuana program. The bill would delete the line in last year’s marijuana legalization law that channels 30 percent of revenues into a marijuana equity investment fund. Although Democrats still control the state Senate, minority business advocates worry that the bill could still pass and are calling the bill an effort to dismantle provisions in the law that have strong public support. If the bill does not pass, the funding will go supporting licensing opportunities for small and minority-owned marijuana businesses.

Harm Reduction

New Jersey Legislature Approves Bills Ending Requirement for Municipal Approval for Needle Exchanges. The legislature has passed the Syringe Access Bill  (S-3009/A-4847) and the Syringe Decrim Bill  (S-3493/A-5458), a pair of bills whose aim is to address the state’s opioid overdose epidemic by easing access to clean needles, legalizing possession of needles, and expanding access to addiction services. The first pair of bills ends the requirement that municipalities pass an ordinance to okay local needle exchanges, while the second pair of bills legalized needle possession.

International

Canada Open Legal Pathway for Access to Psychedelic Treatment with MDMA, Psilocbyin. Health Canada has amended federal regulations to allow doctors to request access to restricted drugs, such as MDMA and psilocybin, for patients undergoing psychedelic therapy. The regulatory change will allow physicians to use the Special Access Program, which allows healthcare practitioners to access drugs that have shown promise in clinical trials, or are approved in other countries, to seek permission to employ the drugs as therapeutics. The amendment to the Food and Drug Regulations was published in the Wednesday edition of the Canada Gazette, Canada’s version of the federal register.